Page 27 - Innovation_Hong_Kong

Novoheart, a stem cell biotechnology company in the Hong Kong Science Park,
engineers the first bio-artificial human heart known as “heart-in-a-jar”,
helping to revolutionise drug development.

BIOTECHNOLOGY A study on lung cancer led by Professor Tony Mok
and a study on nasopharyngeal cancer led by
Professors Allen Chan and Dennis Lo of the
Chinese University of Hong Kong have been
selected by the New England Journal of Medicine,
the most prestigious international medical
journal, as amongst the 10 Notable Articles of
2017 from around 5 000 research papers
received from all over the world.

Through the Innovation and Technology Fund,
we have funded over 460 biotechnology projects
including pioneering ones on non-invasive
prenatal diagnosis, robotics-assisted minimally
invasive surgery and mini artificial heart.

We have more than 100 biotechnology
companies in the Hong Kong Science Park.

HONG KONG / 23